Targeting dendritic cells (DCs) by directing antigens to specific endocytic receptors is a promising approach to improve vaccine efficacy. The C-type lectin receptor DC-SIGN is expressed on the surface of DCs and has been postulated to be a useful target for vaccine design. DC-SIGN recognizes mannosylated or fucosylated glycans and can mediate antigen uptake. To deliver antigens to DCs, we engineered the immunogenic virus-like particle Qβ to present multiple copies of a DC-SIGN ligand and tested the consequences of receptor engagement. Particle uptake by DCs depends on high degree mannosylation with efficient trafficking to early endosomal compartments and an induction of a Th1 type immune response. As such a response is relevant for anti-cancer vaccines, this study highlights the promise of targeting lectin receptors on DCs for anti-cancer vaccines.

Glycan-modified bacteriophage evokes Th1-type (cancer-relevant) immune responses

256th National Meeting (2018)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.